Results 21 to 30 of about 3,487 (207)

Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD

Annals of Clinical and Translational Neurology
Cases of myelin oligodendrocyte glycoprotein (MOG) antibody‐associated disease (MOGAD) co‐occurring with neoplasms have been reported. In this international, retrospective cohort study in South Korea and the USA, 16 of 445 (3.6%) patients with MOGAD had ...
Young Nam Kwon, Nanthaya Tisavipat, Yong Guo, Stephanie B. Syc‐Mazurek, Ji Yeon Han, Jun‐Soon Kim, Kyomin Choi, Seong‐il Oh, Seok‐Jin Choi, Eunhee Sohn, Jeeyoung Oh, Seung Woo Kim, Ha Young Shin, Byung Chan Lim, Byoung Joon Kim, Kyung Seok Park, Jung‐Joon Sung, Se Hoon Kim, Sung‐Hye Park, Anastasia Zekeridou, Claudia F. Lucchinetti, Sean J. Pittock, John J. Chen, Eoin P. Flanagan, Sung‐Min Kim   +24 more
doaj   +3 more sources

A retrospective study of myelin oligodendrocyte glycoprotein antibody-associated disease from a clinical laboratory perspective

Frontiers in Neurology, 2023
ObjectivesTo analyze the differences in laboratory data between patients with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD).MethodsThe study ...
Yufei Wang, Yufei Wang, Yufei Wang, Qusang Danzeng, Qusang Danzeng, Qusang Danzeng, Wencan Jiang, Wencan Jiang, Wencan Jiang, Bingqing Han, Bingqing Han, Bingqing Han, Xiaowen Zhu, Xiaowen Zhu, Xiaowen Zhu, Ziwei Liu, Ziwei Liu, Ziwei Liu, Jialu Sun, Jialu Sun, Jialu Sun, Kelin Chen, Kelin Chen, Kelin Chen, Guojun Zhang, Guojun Zhang, Guojun Zhang   +26 more
doaj   +1 more source

Modelling predictors of relapsing adult MOGAD [PDF]

, 2023
In myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD), only approximately 40%-60% of patients develop a relapsing disease course, for which the preventative treatment is long-term immunotherapy.
Tench, Christopher, Tanasescu, Radu, Human, Matthew, Papathanasiou, Athanasios   +3 more
core   +1 more source

Fatigue is a common symptom in myelin oligodendrocyte glycoprotein antibody disease

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022
Background Unlike multiple sclerosis and neuromyelitis optica, the burden of fatigue in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is unclear.
Dimitrios C Ladakis, Jennifer Gould, Jenny M Khazen, Julia M Lefelar, Scott Tarpey, Charles J Bies, Rebecca Salky, Kathryn C Fitzgerald, Pavan Bhargava, Bardia Nourbakhsh, Elias S Sotirchos   +10 more
doaj   +1 more source

TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-IgG Test Results. [PDF]

Neurol Neuroimmunol Neuroinflamm
Vilaseca A, Filippatou AG, Said Y, Sechi E, Syc-Mazurek SB, Cacciaguerra L, Guo K, Vorasoot N, Niederschweiberer M, Thakolwiboon S, Sagen JA, Lopez-Chiriboga SA, Tillema JM, Chen JJ, Pittock SJ, Sotirchos ES, Flanagan EP.   +16 more
europepmc   +2 more sources

A rare case of myelin oligodendrocyte glycoprotein antibody disease with keratoconus

Indian Journal of Ophthalmology. Case Reports, 2022
Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) consists of a group of inflammatory demyelinating disorders generally associated with optic neuritis and acute disseminated encephalomyelitis (ADEM).
Sunny Makkar, Nisha Ahuja, Sonal Khandelwal   +2 more
doaj   +1 more source

Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients

Neurology and Therapy, 2023
Introduction Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare demyelinating disorder of the central nervous system. Despite increased recognition of MOGAD as a distinct disease and the availability of sensitive methods of
Jonathan D. Santoro, Jennifer Gould, Zoya Panahloo, Ella Thompson, Julia Lefelar, Jacqueline Palace   +5 more
doaj   +1 more source

Clinical and neuroimaging findings in MOGAD–MRI and OCT [PDF]

Clinical and Experimental Immunology, 2021
Abstract Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are rare in both children and adults, and have been recently suggested to be an autoimmune neuroinflammatory group of disorders that are different from aquaporin-4 autoantibody-associated neuromyelitis optica spectrum disorder and from classic multiple ...
Frederik Bartels, Angelo Lu, Frederike Cosima Oertel, Carsten Finke, Friedemann Paul, Claudia Chien   +5 more
openaire   +3 more sources

Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide

Frontiers in Neurology, 2023
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the central nervous system (CNS) with the presence of conformation-sensitive antibodies against MOG.
Jyh Yung Hor, Kazuo Fujihara, Kazuo Fujihara   +2 more
doaj   +1 more source

The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON

BMC Neurology, 2022
Background Antibodies against myelin-oligodendrocyte-glycoprotein (MOG-Abs) associated disease (MOGAD) has been recognized as a disease entity. Optic neuritis (ON) is the most common symptom in MOGAD.
Yajun Yao, Xindi Li, Yun Xu, Xiaofang Liang, Liu Yang, Fu-Dong Shi, Xinghu Zhang, De-Cai Tian, Xuxiang Zhang   +8 more
doaj   +1 more source